FoRx Therapeutics AG
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which received IND clearance and moved into clinical Phase 1 in H2 2025. Preclinically, the compound has shown strong and convincing evidence for best-in-class potential, having demonstrated excellent tolerability and greatly superior anti-tumor efficacy in multiple in vivo tumor models vs. competition. In the clinic, FORX-428 is being evaluated in an open-label study, initially taking place in the United States, to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options. An initial data readout from the clinical trial is expected in H2 2026
Company HQ City:
Basel
Company HQ State:
Basel-Stadt
Company HQ Country:
Switzerland
Year Founded:
2019
Lead Product in Development:
FORX-428, a PARG inhibitor (small molecule)
CEO
Tarig Bashir
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
Sept / Oct 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}